priority review

GSK's asthma drug Nucala gets speedy review for rare blood disorder
GSK's asthma drug Nucala gets speedy review for rare blood disorder
Endpoints
GSK
FDA
Nucala
hypereosinophilic syndrome
HES
priority review
Flag link:
Sanofi nabs speedy review of sutimlimab, aiming for a November approval
Sanofi nabs speedy review of sutimlimab, aiming for a November approval
Fierce Biotech
Sanofi
cold agglutinin disease
sutimlimab
FDA
priority review
Flag link:
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
Europe
priority review
EMA
Flag link:
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC
Pharmaceutical Business Review
Takeda
Alunbrig
brigatinib
FDA
priority review
non-small cell lung cancer
Flag link:
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review
Motley Fool
FDA
Biomarin
priority review
valrox
gene therapy
hemophilia A
Flag link:
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Motley Fool
Roche
FDA
priority review
Tecentriq
non-squamous non-small cell lung cancer
non-small cell lung cancer
Flag link:
Vifor buys priority review voucher for undisclosed filing
Vifor buys priority review voucher for undisclosed filing
Fierce Biotech
Vifor
priority review vouchers
FDA
priority review
Flag link:
Jazz targets US launch of SCLC drug after FDA grants fast review
Jazz targets US launch of SCLC drug after FDA grants fast review
Pharmaforum
PharmaMar
Jazz Pharmaceuticals
FDA
small cell lung cancer
lurbinectedin
priority review
Flag link:
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Motley Fool
Seattle Genetics
tucatinib
FDA
priority review
breast cancer
HER-2 postive breast cancer
Flag link:
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Fierce Biotech
Bristol-Myers Squibb
FDA
lisocabtagene maraleucel
priority review
CAR-T
Flag link:
Deciphera nabs speedy review for GIST cancer hopeful
Deciphera nabs speedy review for GIST cancer hopeful
Fierce Biotech
Deciphera Pharma
FDA
priority review
ripretinib
GIST
Flag link:
FDA Speeds Up Examination of 5 Drugs with Priority Review
FDA Speeds Up Examination of 5 Drugs with Priority Review
BioSpace
FDA
priority review
capmatinib
Kite Pharma
KTE-X19
Eli Lilly
selpercatinib
GSK
belantamab mafodotin
Astex
C-DEC
Flag link:
FDA Grants Priority Review For Kite's KTE-X19 BLA
FDA Grants Priority Review For Kite's KTE-X19 BLA
NASDAQ
Gilead Sciences
Kite Pharma
KTE-X19
priority review
FDA
mantle cell lymphoma
Flag link:
GSK nabs speedy review for one of its top prospects
GSK nabs speedy review for one of its top prospects
Fierce Biotech
GSK
FDA
priority review
BCMA
belantamab mafodotin
relapsed or refractory multiple myeloma
Flag link:
FDA Gives Clovis Oncology's Rubraca a Priority Review
FDA Gives Clovis Oncology's Rubraca a Priority Review
Motley Fool
Clovis Oncology
Rubraca
FDA
priority review
Flag link:
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Flag link:
FDA rushed to approve 48 drugs in 2019, sometimes way ahead of schedule. Could that be dangerous?
FDA rushed to approve 48 drugs in 2019, sometimes way ahead of schedule. Could that be dangerous?
Endpoints
FDA
drug approvals
priority review
Flag link:
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Pharmaceutical Business Review
Merck
Keytruda
bladder cancer
priority review
NMIBC
FDA
Flag link:
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
Pharmaceutical Business Review
FDA
Incyte
priority review
pemigatinib
cholangiocarcinoma
Flag link:
Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease
Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye disease
Pharmaceutical Business Review
Horizon Therapeutics
FDA
teprotumumab
thyroid eye disease
priority review
Flag link:

Pages